Cost-effectiveness of PCSK9 inhibitors
Pro Research Analysisby 
Searched over 200M research papers
PCSK9 Inhibitors Cost-Effectiveness: Overview and Key Metrics
PCSK9 inhibitors are effective at lowering LDL cholesterol and reducing cardiovascular events, but their high cost has raised concerns about their value for money in healthcare systems worldwide. The main measure used to assess cost-effectiveness is the incremental cost-effectiveness ratio (ICER), which compares the additional cost per quality-adjusted life year (QALY) gained with PCSK9 inhibitors versus standard therapies like statins or ezetimibe. Across multiple studies and countries, current ICERs for PCSK9 inhibitors are much higher than commonly accepted thresholds for cost-effectiveness, which typically range from $45,000 to $150,000 per QALY depending on the country Bonow2017Kumar2018Korman2017+6 MORE.
High ICERs and Price Barriers
Most analyses report ICERs for PCSK9 inhibitors between $197,000 and $625,000 per QALY in the US, and similarly high values in other countries, far exceeding accepted thresholds Bonow2017Kumar2018Korman2017+6 MORE. For example, in the US, the annual cost of PCSK9 inhibitors is about $14,000–$15,000, and studies consistently find that the price would need to be reduced by 62–71% (to around $4,250–$5,500 per year) to meet the $100,000 per QALY threshold Bonow2017Kumar2018Kazi2016+2 MORE. In Australia, the price would need to drop from AU$8,174 to about AU$1,500 per year to be considered cost-effective . In Europe, similar reductions are needed, with cost-effectiveness only seen in very high-risk patients or at much lower drug prices Arrieta2017Korman2018Wisløff2019.
Subgroup and Country-Specific Findings
Cost-effectiveness is more favorable in certain high-risk groups, such as older patients with established cardiovascular disease, those with heterozygous familial hypercholesterolemia, or patients with multiple comorbidities and very high annual risk Arrieta2017Korman2018Hlatky2017. However, even in these groups, the drugs are only cost-effective at current prices in a minority of scenarios, and assumptions about clinical effectiveness can significantly change the results Arrieta2017Korman2018Hlatky2017. In Norway and other European countries, PCSK9 inhibitors are generally not cost-effective except in select high-risk subgroups or if lower prices are negotiated Arrieta2017Wisløff2019Hlatky2017.
Impact on Healthcare Budgets and Access
Widespread use of PCSK9 inhibitors at current prices would have a major impact on healthcare budgets, increasing drug expenditures substantially without corresponding savings in cardiovascular care costs Arrieta2017Dressel2019Korman2018. This restricts access to these drugs, especially for lower-income patients, and may worsen health disparities . Private payers also find PCSK9 inhibitors unprofitable, with negative returns on investment at current prices .
Need for Price Reductions and Further Research
All studies agree that significant price reductions are necessary for PCSK9 inhibitors to be considered cost-effective for broader populations Bonow2017Kumar2018Korman2017+6 MORE. Future research is needed to clarify long-term benefits, especially on mortality, and to refine cost-effectiveness models for different patient groups Bonow2017Arrieta2017Hlatky2017. Alternative pricing strategies, such as outcomes-based pricing, may also help improve value .
Conclusion
PCSK9 inhibitors are clinically effective but not cost-effective at current prices in most settings and populations. Major price reductions or targeted use in very high-risk patients are needed to align with accepted cost-effectiveness thresholds. Until then, their widespread use is limited by economic considerations, and further research and innovative pricing models are warranted to improve their value proposition.
Sources and full results
Most relevant research papers on this topic